Tranquillisation or asleep ‐ not asleep by 12 hours · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep ‐ not asleep by 12 hours compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Global outcome: specific Not sedated at 60 minutes * · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: specific Not sedated at 60 minutes * compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ Aggression ‐ no overall improvement · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes specific behaviour ‐ aggression ‐ no overall improvement compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Global outcome: no change at 48 hours CGI · patients to psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome: no change at 48 hours CGI compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
Adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) · patients to psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ rigidity between 0‐3 days (IM phase) compared with OTHER ANTIPSYCHOTIC: d. LOXAPINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients to psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquilisation or asleep · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquilisation or asleep compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ not reported · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes repeated need for tranquillisation compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes specific behaviour ‐ threat or injury to self or others compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Global outcome ‐ need for benzodiazepine during 24 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome ‐ need for benzodiazepine during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia during 24 hours · psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia during 24 hours compared with OTHER ANTIPSYCHOTIC: e. OLANZAPINE (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome ‐ overall improvement (not any improvement) · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome ‐ overall improvement (not any improvement) compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Specific behaviour ‐ injury or threat of self to others ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global outcome: general ‐ no improvement · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes global outcome: general ‐ no improvement compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Adverse effect: Specific ‐ hypotensive episode · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effect: Specific ‐ hypotensive episode compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review
Adverse effect ‐ discontinued due to EPS · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effect ‐ discontinued due to EPS compared with OTHER ANTIPSYCHOTIC: f. PERPHENAZINE (very low certainty).
1 finding from 1 review